Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK3486 cardiac repolarization study in healthy subjects
NCT06795204Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cycloprofol (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Change-from-baseline in QTc Interval at 24 hours. Started Apr 2024; status: completed.
02
Drugs
cycloprofol
Beyond the preview
Go deeper on NCT06795204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795204.